Physician profile
Rajendrakumar Patel
NPI 1265792444
$3,154.93
in general payments reported to CMS, 2019-2025
24 companies · $1,163 in 2025
The $1,163 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $105 · 2022: $180 · 2023: $587 · 2024: $1,120 · 2025: $1,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,870.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $923.65 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $417.31 | 2021-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $300.93 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $268.38 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lundbeck LLC | $153.19 | 2024-2025 | Rexulti |
| Pfizer INC. | $132.01 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $114.51 | 2024-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $105.36 | 2025 | |
| Abbvie INC. | $101.74 | 2023-2025 | |
| Exact Sciences Corporation | $96.90 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $90.52 | 2024-2025 | Gemtesa |
| Abbott Laboratories | $88.01 | 2023-2025 | Freestyle Libre 3 |
| Ucb, INC. | $64.63 | 2022 | |
| Novartis Pharmaceuticals Corporation | $58.70 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.08 | 2021-2025 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $44.61 | 2023 | |
| Amgen INC. | $29.42 | 2023-2024 | Evenity, Prolia |
| Abiomed | $24.47 | 2024 | Impella |
| Dexcom, INC. | $18.25 | 2024 | Dexcom G6 Transmitter |
| Alnylam Pharmaceuticals INC. | $17.10 | 2025 | Onpattro |
| Axsome Therapeutics, INC. | $15.48 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $14.86 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $14.83 | 2023 | Dificid |
| Biohaven Pharmaceutical Holding Company LTD. | $12.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajendrakumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.